Skip to main content
    B

    Beam Therapeutics Inc (BEAM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $20.65
    -0.29 (-1.38%)

    Market Cap: $2.36B

    Last updated: Nov 17, 2026 at 4:39 PM ET

    Beam Therapeutics Inc (BEAM) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Beam Therapeutics (BEAM) has a market cap of $2.36B and an enterprise value of $2.25B. Revenue grew 163.27% over the last 12 months from the 12 months before. It kept -73.04% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 4.72% below the market cap, as cash exceeds debt.

    Market Cap$2.36B
    Enterprise Value$2.25B
    Latest price (Nov 17, 2026)$20.65

    Key Dates

    The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 22, 2027 (expected)
    Last Earnings DateNov 3, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.36% in the quarter ended Sep 30, 2026 and grew 12.71% a year over 2 years.

    Shares Outstanding104.70M
    Shares Change (YoY)+2.07%
    Shares Change (QoQ)+0.36%
    Share Count Growth (2Y CAGR)+12.71%

    Valuation Ratios

    Sales and book value multiples are 14.7x and 2.3x. Its year-end P/S ranged from 5.9x to 104.5x from 2021 to 2025.

    P/S Ratio14.7x
    Forward P/S61.4x
    P/B Ratio2.3x

    Valuation history and multiples

    Price Statistics

    The stock is down 4.93% over 52 weeks and trades 16.90% below its 50-day average.

    Beta (1Y)2.22
    52-Week Change-4.93%
    1-Month Change-14.63%
    3-Month Change-28.96%
    6-Month Change-21.57%
    5-Year Change-69.33%
    Total Return (1Y)-4.93%
    Total Return (3Y CAGR)-9.07%
    Total Return (5Y CAGR)-25.47%
    Return vs SPY (1Y)-17.35%
    Max Drawdown (1Y)-45.54%
    Max Drawdown (3Y)-67.74%
    Sharpe Ratio (1Y)-0.08
    Correlation with SPY (1Y)0.43
    50-Day Average$24.85
    200-Day Average$27.80
    52-Week Range$20.23 to $38.26
    RSI (14 Days)34.5
    Average Volume (20 Days)2.15M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 13.00x current liabilities, and total debt is 0.11x shareholder equity.

    Current Ratio13.00x
    Quick Ratio13.00x
    Debt / Equity0.11x
    Interest Coverage11.64x

    Returns and Efficiency

    Return on invested capital is -29.73% over the last 12 months, against a 5-year average of -24.12%.

    Return on Equity (ROE)-11.24%
    Return on Assets (ROA)-8.44%
    Return on Invested Capital (ROIC)-29.73%
    ROE (5Y Average)-31.11%
    ROA (5Y Average)-19.06%
    ROIC (5Y Average)-24.12%
    Asset Turnover0.11x

    Scores

    BEAM has an Altman Z-Score of 1.92, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score1.92
    Altman Z ZoneGrey
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $146.64M over the last 12 months.

    Revenue$146.64M
    Revenue Growth (YoY)+163.27%
    Gross Profit$146.64M
    Operating Income-$392.54M
    Pretax Income-$107.10M
    Net Income-$107.10M
    Reported EPS (TTM)-$1.04

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 75.01% of the $1.27B in total assets.

    Cash and Equivalents$213.27M
    Total Debt$101.85M
    Net Cash$111.42M
    Net Cash Per Share$1.06
    Working Capital$985.30M
    Shareholder Equity$952.67M
    Book Value Per Share$9.10
    Total Assets$1.27B
    Total Liabilities$316.40M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $9.59M of capital spending, operating cash flow left -$398.24M of free cash flow.

    Operating Cash Flow-$388.65M
    Capital Expenditures$9.59M
    Free Cash Flow-$398.24M
    FCF Per Share-$3.86
    Depreciation and Amortization$33.39M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -267.68%.

    Gross Margin100.00%
    Operating Margin-267.68%
    Pretax Margin-73.04%
    Net Margin-73.04%
    FCF Margin-271.57%

    Growth

    Revenue grew 31.88% a year over 3 years.

    Revenue Growth (3Y CAGR)+31.88%
    Revenue Growth (5Y CAGR)+466.27%
    Book Value Per Share Growth (2Y CAGR)-0.27%
    Tangible Book Per Share Growth (2Y CAGR)-0.27%

    Revenue and profit by year

    Dividends and Yields

    BEAM does not pay a dividend. Its free cash flow yield is -18.42%.

    FCF Yield-18.42%
    Buyback Yield-0.13%
    Shareholder Yield-0.13%

    Peer Position

    Against 7 similar companies, BEAM has the 4th highest P/S.

    P/S Ratio14.7x vs 5.2x median
    ROIC-29.73% vs -42.31% median
    Revenue Growth (Trailing 4 Quarters, YoY)+163.27% vs -100.00% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -52.73% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-52.73%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About BEAM

    What is BEAM's market cap?

    Beam Therapeutics has a market cap of $2.36B. Its enterprise value, which adds debt and subtracts cash, is $2.25B.

    How many shares of BEAM are outstanding?

    Beam Therapeutics has 104.70M shares outstanding. The count is up 2.07% from a year earlier.

    Does BEAM pay a dividend?

    No. Beam Therapeutics does not pay a dividend.

    How much debt does BEAM have?

    Beam Therapeutics has $101.85M of total debt and $213.27M of cash and equivalents, a net cash position of $111.42M.